Creso Pharma Limited Logo

Creso Pharma Limited

COPHF

(1.2)
Stock Price

0,12 USD

-228.41% ROA

-130.99% ROE

-0.02x PER

Market Cap.

761.003,00 USD

-237.7% DER

0% Yield

-377.28% NPM

Creso Pharma Limited Stock Analysis

Creso Pharma Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Creso Pharma Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (30%), which means it has a small amount of debt compared to the ownership it holds

3 Assets Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

4 ROE

The stock's ROE indicates a negative return (-130.99%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-148.11%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Creso Pharma Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Creso Pharma Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Sell

Creso Pharma Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Creso Pharma Limited Revenue
Year Revenue Growth
2013 0
2014 20.925 100%
2015 0 0%
2016 8.022 100%
2017 243.798 96.71%
2018 578.222 57.84%
2019 3.626.427 84.06%
2020 2.447.761 -48.15%
2021 6.218.337 60.64%
2022 8.689.000 28.43%
2023 32.475.928 73.24%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Creso Pharma Limited Research and Development Expenses
Year Research and Development Expenses Growth
2013 0
2014 0 0%
2015 0 0%
2016 488.978 100%
2017 788.623 38%
2018 286.539 -175.22%
2019 286.026 -0.18%
2020 344.989 17.09%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Creso Pharma Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 0
2014 675 100%
2015 0 0%
2016 2.398.975 100%
2017 5.195.710 53.83%
2018 10.838.659 52.06%
2019 5.640.898 -92.14%
2020 3.264.433 -72.8%
2021 4.349.916 24.95%
2022 6.214.000 30%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Creso Pharma Limited EBITDA
Year EBITDA Growth
2013 0
2014 -9.126 100%
2015 0 0%
2016 -4.201.465 100%
2017 -12.963.655 67.59%
2018 -15.948.919 18.72%
2019 -9.807.158 -62.63%
2020 -16.486.854 40.52%
2021 -28.058.485 41.24%
2022 -17.618.000 -59.26%
2023 -4.838.983 -264.08%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Creso Pharma Limited Gross Profit
Year Gross Profit Growth
2013 -249
2014 -8.451 97.05%
2015 0 0%
2016 -24.806 100%
2017 -193.899 87.21%
2018 224.656 186.31%
2019 2.125.890 89.43%
2020 -3.882.415 154.76%
2021 -400.611 -869.12%
2022 287.000 239.59%
2023 7.668.308 96.26%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Creso Pharma Limited Net Profit
Year Net Profit Growth
2013 -249
2014 -9.953 97.5%
2015 -138.864 92.83%
2016 -4.584.239 96.97%
2017 -15.076.076 69.59%
2018 -16.756.036 10.03%
2019 -15.054.381 -11.3%
2020 -30.779.581 51.09%
2021 -30.030.967 -2.49%
2022 -32.782.000 8.39%
2023 -65.885.888 50.24%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Creso Pharma Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 0
2014 0 0%
2015 -3 100%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 -10 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Creso Pharma Limited Free Cashflow
Year Free Cashflow Growth
2013 0
2014 0 0%
2015 0 0%
2016 -2.570.622 100%
2017 -7.579.021 66.08%
2018 -15.460.117 50.98%
2019 -13.509.187 -14.44%
2020 -10.050.730 -34.41%
2021 -22.832.230 55.98%
2022 -17.654.000 -29.33%
2023 -1.691.056 -943.96%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Creso Pharma Limited Operating Cashflow
Year Operating Cashflow Growth
2013 0
2014 0 0%
2015 0 0%
2016 -2.565.126 100%
2017 -7.538.133 65.97%
2018 -8.100.789 6.95%
2019 -10.166.956 20.32%
2020 -9.621.580 -5.67%
2021 -22.377.916 57%
2022 -17.306.000 -29.31%
2023 -1.539.243 -1024.32%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Creso Pharma Limited Capital Expenditure
Year Capital Expenditure Growth
2013 0
2014 0 0%
2015 0 0%
2016 5.496 100%
2017 40.888 86.56%
2018 7.359.328 99.44%
2019 3.342.231 -120.19%
2020 429.150 -678.8%
2021 454.314 5.54%
2022 348.000 -30.55%
2023 151.813 -129.23%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Creso Pharma Limited Equity
Year Equity Growth
2015 -10.771
2016 3.239.851 100.33%
2017 21.028.634 84.59%
2018 16.504.392 -27.41%
2019 17.273.960 4.46%
2020 13.652.171 -26.53%
2021 27.758.612 50.82%
2022 22.294.000 -24.51%
2023 -4.058.000 649.38%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Creso Pharma Limited Assets
Year Assets Growth
2015 801
2016 3.767.873 99.98%
2017 21.595.904 82.55%
2018 22.282.294 3.08%
2019 22.663.609 1.68%
2020 19.120.608 -18.53%
2021 29.314.106 34.77%
2022 37.982.000 22.82%
2023 19.044.000 -99.44%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Creso Pharma Limited Liabilities
Year Liabilities Growth
2015 11.572
2016 528.022 97.81%
2017 567.270 6.92%
2018 5.777.902 90.18%
2019 5.389.649 -7.2%
2020 5.468.437 1.44%
2021 1.555.494 -251.56%
2022 15.688.000 90.08%
2023 23.102.000 32.09%

Creso Pharma Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.85
Net Income per Share
-5.12
Price to Earning Ratio
-0.02x
Price To Sales Ratio
0.06x
POCF Ratio
-0.15
PFCF Ratio
-0.13
Price to Book Ratio
-0.2
EV to Sales
0.76
EV Over EBITDA
-1.13
EV to Operating CashFlow
-1.78
EV to FreeCashFlow
-1.71
Earnings Yield
-43.75
FreeCashFlow Yield
-7.45
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
8.23
Graham NetNet
-2.82

Income Statement Metrics

Net Income per Share
-5.12
Income Quality
0.23
ROE
-113.71
Return On Assets
-0.86
Return On Capital Employed
-0.88
Net Income per EBT
1
EBT Per Ebit
1.68
Ebit per Revenue
-2.25
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.03
Operating Profit Margin
-2.25
Pretax Profit Margin
-3.77
Net Profit Margin
-3.77

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.79
Free CashFlow per Share
-0.82
Capex to Operating CashFlow
-0.04
Capex to Revenue
0.02
Capex to Depreciation
0.26
Return on Invested Capital
-1.57
Return on Tangible Assets
-2.28
Days Sales Outstanding
85.01
Days Payables Outstanding
218.56
Days of Inventory on Hand
35.62
Receivables Turnover
4.29
Payables Turnover
1.67
Inventory Turnover
10.25
Capex per Share
0.03

Balance Sheet

Cash per Share
0,10
Book Value per Share
-0,59
Tangible Book Value per Share
-1.11
Shareholders Equity per Share
-0.59
Interest Debt per Share
2.26
Debt to Equity
-2.38
Debt to Assets
0.51
Net Debt to EBITDA
-1.04
Current Ratio
0.24
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
-4248000
Working Capital
-0,02 Bil.
Intangibles to Total Assets
0.19
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
1461000
Debt to Market Cap
12.68

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Creso Pharma Limited Dividends
Year Dividends Growth

Creso Pharma Limited Profile

About Creso Pharma Limited

Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates, processes, and sells cannabis products, as well as supplies cannabis retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.

CEO
Mr. William Lay B.Com.
Employee
0
Address
145 Stirling Highway
Nedlands, 6009

Creso Pharma Limited Executives & BODs

Creso Pharma Limited Executives & BODs
# Name Age
1 Ms. Micheline MacKay B.Sc., M.Sc., P.M.P.
Executive Director
70
2 Brett Ayers
Managing Director of Impactive
70
3 Mr. Winton William Willesee C.P.A., GAICD, MAICD, MCom
Joint Company Secretary
70
4 Hon. Brian Walker
Strategic Consultant & Chair of Scientific Advisory Committee
70
5 Mr. Mitchel Fleming
Managing Director of Halucenex
70
6 Dr. Gian Trepp
Commercial & Marketing Director
70
7 Mr. Christopher Grundy BCom, FCA, FCIS, GAICD
Chief Financial Officer
70
8 Mr. Boaz Wachtel M.A., M.D., MBA
Co-Founder & Non-Executive Chairman
70
9 Mr. William Lay B.Com.
Group Chief Executive Officer, MD & Director
70

Creso Pharma Limited Competitors